High-level psychotropic polypharmacy: a retrospective comparison of children in foster care to their peers on Medicaid

Table 3 Predicting Duration of High-Level Psychotropic Polypharmacy^a

Variables	IRR^b	Lower Limit	Upper Limit	p
Residence - Metro	*ref*
Non-metro	1.02	0.96	1.09	0.462
Sex - Female	*ref*
Male	1.04	0.97	1.11	0.268
Age Category - 12-17 years	*ref*
6–11 years	0.96	0.9	1.02	0.196
Race/Ethnicity – White, Non-Hispanic	*ref*
Black, Non-Hispanic	1.09	0.98	1.22	0.097
Hispanic	1.05	0.86	1.31	0.641
Other	0.92	0.77	1.1	0.341
Foster Care	0.96	0.88	1.05	0.319
Diagnostic Categories
Schizophrenia and Other Psychotic Processes	0.95	0.84	1.08	0.446
Mood Disorders Total	0.96	0.89	1.03	0.259
Autism	1.06	0.98	1.15	0.153
Other Neurodevelopmental Disorders	1.12	1.04	1.21	0.002
Disruptive Behavior Disorders	1.18	1.04	1.34	0.011
Anxiety and Trauma Related Disorders	0.95	0.89	1.01	0.118
Impulse Control	0.9	0.81	0.99	0.030
Sleep-Wake Disorders	0.92	0.85	1.01	0.069

^aamong children with at least one antipsychotic medication prescription and at least 30 days of high-level psychotropic polypharmacy; ^bincidence rate ratio (IRR)